8-K: Larimar Therapeutics Provides Update on Nomlabofusp Development for Friedreich's Ataxia

Larimar Therapeutics is advancing its lead candidate, nomlabofusp, for Friedreich's ataxia, with positive data from ongoing studies and plans for a BLA submission in the second half of 2025.

Summary

• Larimar Therapeutics is developing nomlabofusp (CTI-1601), a protein replacement therapy for Friedreich's ataxia (FA).
• Nomlabofusp is designed to deliver frataxin protein directly to the mitochondria, addressing the underlying cause of FA.
• The company has received several designations for nomlabofusp, including Orphan Drug, Rare Pediatric Disease, Fast Track, PRIME, and ILAP.
• Larimar was selected by the FDA to participate in its START pilot program.
• Clinical trials have shown that nomlabofusp is generally well-tolerated and increases frataxin levels in tissues.
• In a Phase 2 dose exploration study, a 50 mg dose of nomlabofusp increased frataxin levels in skin cells from less than 17% of healthy volunteer levels at baseline to 33-59% after 14 days of daily dosing.
• Long-term open-label extension (OLE) study data shows that a 25 mg daily dose of nomlabofusp increased frataxin levels in buccal cells from 15% of healthy volunteer levels at baseline to 30% at Day 90, and in skin cells from 16% to 72% at Day 90.
• Early trends towards improvements in clinical outcomes were observed at Day 90 in the OLE study.
• The company is increasing the dose to 50 mg in the OLE study and starting newly enrolled participants on 50 mg daily.
• Larimar is targeting a Biologics License Application (BLA) submission for nomlabofusp in the second half of 2025.
• A global confirmatory/registration study is on track to begin in mid-2025.
• A pediatric PK run-in study is ongoing, with dosing expected to begin in early 2025 for adolescents and in the first half of 2025 for children.
• Larimar has approximately $204 million in cash and investments as of September 30, 2024, providing a projected cash runway into Q2 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Larimar Therapeutics, with strong clinical data, a clear regulatory pathway, and a solid financial position. The company is making good progress towards a BLA submission, and the data suggests that nomlabofusp has the potential to be a significant treatment for Friedreich's ataxia.

Positives

• Nomlabofusp has shown dose-dependent increases in frataxin levels in tissues.
• The drug has been generally well-tolerated in clinical trials.
• Early trends suggest potential clinical benefits.
• The company has a strong cash position.
• Nomlabofusp has received multiple regulatory designations.
• The company is actively pursuing an accelerated approval pathway with the FDA.
• The company has a strong IP portfolio with patent protection extending to 2040.
• Nomlabofusp has demonstrated the ability to deliver sufficient amounts of FXN to mitochondria in preclinical studies.
• Nomlabofusp has shown positive results in a cardiac mouse model of FA, preventing left ventricle dilation and preserving function.

Negatives

• The document notes that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially.
• The company is still in the clinical trial phase and has not yet received regulatory approval for nomlabofusp.
• The document mentions that the company needs to raise capital to conduct its product development activities.
• There is a risk that the FDA may not agree with Larimar's nomlabofusp development strategy.
• The document mentions that preliminary clinical trial results may differ from final clinical trial results.

Risks

• The success, cost, and timing of Larimar's product development activities, nonclinical studies, and clinical trials are uncertain.
• Preliminary clinical trial results may differ from final clinical trial results.
• The FDA may not ultimately agree with Larimar's nomlabofusp development strategy.
• Public health crises could impact Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines, and operations.
• Larimar's ability to obtain regulatory approvals for nomlabofusp and future product candidates is not guaranteed.
• The company's ability to raise the necessary capital to conduct its product development activities is a risk.
• There is a risk that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later non-clinical or clinical trials, and assessments.

Future Outlook

Larimar intends to pursue an accelerated approval pathway with a BLA submission targeted for the second half of 2025. The company is also advancing discussions with the FDA on the potential use of FXN levels to support accelerated approval. They are also planning to initiate a global confirmatory/registration study in mid-2025 and continue the open-label extension study with a 50 mg daily dose.

Management Comments

• Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

Industry Context

The document highlights the competitive landscape for FA treatments, noting that nomlabofusp is a potential first-and-only protein replacement therapy designed to address the underlying cause of FA. This positions Larimar as a key player in the development of novel therapies for this rare disease, differentiating it from other approaches such as mitochondrial oxidative stress modifiers and gene therapy.

Comparison to Industry Standards

• The document compares nomlabofusp to other FA treatments in development, such as Biogen's Omaveloxolone (SKYCLARYS), which is an Nrf2 activator, and PTC Therapeutics' Vatiquinone, a 15-Lipoxygenase Inhibitor.
• Unlike these treatments, nomlabofusp is a protein replacement therapy designed to directly address the frataxin deficiency, which is the root cause of FA.
• The document also mentions gene therapy approaches from companies like Design Therapeutics and Lexeo Therapeutics, which are in earlier stages of development.
• The data presented on frataxin levels achieved with nomlabofusp, particularly the increase to 72% of healthy volunteer levels in skin cells at Day 90, is a significant result compared to the baseline levels of 20-40% typically seen in FA patients.
• The document also references a non-interventional study measuring FXN in homozygous healthy volunteers, which provides a benchmark for the effectiveness of nomlabofusp.

Stakeholder Impact

• Shareholders: The positive clinical data and progress towards regulatory approval are likely to be viewed favorably by shareholders.
• Patients: The development of nomlabofusp offers hope for a new treatment option for Friedreich's ataxia.
• Employees: The company's progress and financial stability provide a positive outlook for employees.
• Investors: The company's progress and financial stability provide a positive outlook for investors.
• Analysts: The company's progress and financial stability provide a positive outlook for analysts.

Next Steps

• Initiate dosing in the pediatric PK run-in study for adolescents in early 2025.
• Initiate the PK run-in study in children in the first half of 2025.
• Initiate the global confirmatory/registration study in mid-2025.
• Obtain long-term data from the 50 mg dose in the OLE study by mid-2025.
• Submit a BLA for nomlabofusp in the second half of 2025.

Key Dates

Keywords

Friedreich's ataxia, nomlabofusp, CTI-1601, frataxin, protein replacement therapy, clinical trials, FDA, accelerated approval, rare disease, mitochondria, BLA, biologics license application